0001628280-21-012169.txt : 20210614
0001628280-21-012169.hdr.sgml : 20210614
20210614161039
ACCESSION NUMBER: 0001628280-21-012169
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210610
FILED AS OF DATE: 20210614
DATE AS OF CHANGE: 20210614
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ADAMS THOMAS PHD
CENTRAL INDEX KEY: 0001234366
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35558
FILM NUMBER: 211014717
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cardiff Oncology, Inc.
CENTRAL INDEX KEY: 0001213037
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 272004382
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 11055 FLINTKOTE AVENUE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-952-7570
MAIL ADDRESS:
STREET 1: 11055 FLINTKOTE AVENUE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: Trovagene, Inc.
DATE OF NAME CHANGE: 20130304
FORMER COMPANY:
FORMER CONFORMED NAME: TrovaGene Inc.
DATE OF NAME CHANGE: 20110830
FORMER COMPANY:
FORMER CONFORMED NAME: XENOMICS INC
DATE OF NAME CHANGE: 20040719
4
1
wf-form4_162370142446711.xml
FORM 4
X0306
4
2021-06-10
0
0001213037
Cardiff Oncology, Inc.
CRDF
0001234366
ADAMS THOMAS PHD
C/O CARDIFF ONCOLOGY, INC.
11055 FLINTKOTE AVENUE
SAN DIEGO
CA
92121
0
0
0
1
Former Director
Stock Options
447.84
2021-06-10
4
J
0
272
0
A
2023-06-10
Common Stock
272.0
477870
D
Stock Options
7.18
2021-06-10
4
J
0
223
0
A
2016-03-17
2023-06-10
Common Stock
223.0
477870
D
Stock Options
5.18
2021-06-10
4
J
0
223
0
A
2017-01-04
2023-06-10
Common Stock
223.0
477870
D
Stock Options
51.84
2021-06-10
4
J
0
530
0
A
2018-10-04
2023-06-10
Common Stock
530.0
477870
D
Stock Options
21.6
2021-06-10
4
J
0
755
0
A
2019-01-23
2023-06-10
Common Stock
755.0
477870
D
Stock Options
2.48
2021-06-10
4
J
0
298320
0
A
2020-12-29
2023-06-10
Common Stock
298320.0
477870
D
Stock Options
2.6
2021-06-10
4
J
0
173145
0
A
2020-12-29
2023-06-10
Common Stock
173145.0
477870
D
Expiration date of the stock options was extended to June 10, 2023.
7,338 of the stock options vest immediately. 4,077 of the stock options vest on each of 2/25/2015 and 2016 and 4,076 of the stock options vest on 2/25/2017.
In connection with the Reporting Person's separation agreement dated December 21, 2020, the Compensation Committee accelerated the vesting of such stock options to December 29, 2020.
/s/ Thomas Adams
2021-06-14